The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lanoxin     4-[3-[5-[5-(4,5-dihydroxy-6- methyl-oxan-2...

Synonyms: Cogoxin, Digocin, Digoxin 96%, AGN-PC-00YHTD, SureCN126382, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of digoxin


Psychiatry related information on digoxin

  • The serum digoxin test and digoxin toxicity: a Bayesian approach to decision making [7].
  • In a previous study using somatic cell fusion for Ig chain recombination we demonstrated that a recombinant antibody consisting of the H chain of antibody 26-10 and the L chain of antibody 40-20 retained digoxin binding and the 26-10 Id, but displayed a binding specificity pattern dominated by the 26-10 H chain donor [8].
  • Resumption of physical activity resulted in gradual decline of plasma digoxin, and subsequent strenuous exercise reduced the value to preimmobilization level [9].
  • Visual hallucinations as the earliest symptom of digoxin intoxication [10].
  • This approach has been less successful with digoxin because patient compliance, the proportion absorbed and liver clearance are not yet predictable [11].

High impact information on digoxin


Chemical compound and disease context of digoxin


Biological context of digoxin


Anatomical context of digoxin


Associations of digoxin with other chemical compounds


Gene context of digoxin


Analytical, diagnostic and therapeutic context of digoxin


  1. Asymptomatic digoxin toxicity. Harris, M.M., Hariprasad, M.K., Khalid, S. N. Engl. J. Med. (1981) [Pubmed]
  2. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. Smith, T.W., Butler, V.P., Haber, E., Fozzard, H., Marcus, F.I., Bremner, W.F., Schulman, I.C., Phillips, A. N. Engl. J. Med. (1982) [Pubmed]
  3. Heart failure in outpatients: a randomized trial of digoxin versus placebo. Lee, D.C., Johnson, R.A., Bingham, J.B., Leahy, M., Dinsmore, R.E., Goroll, A.H., Newell, J.B., Strauss, H.W., Haber, E. N. Engl. J. Med. (1982) [Pubmed]
  4. Long-term digitalis therapy improves left ventricular function in heart failure. Arnold, S.B., Byrd, R.C., Meister, W., Melmon, K., Cheitlin, M.D., Bristow, J.D., Parmley, W.W., Chatterjee, K. N. Engl. J. Med. (1980) [Pubmed]
  5. Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study. Muller, J.E., Turi, Z.G., Stone, P.H., Rude, R.E., Raabe, D.S., Jaffe, A.S., Gold, H.K., Gustafson, N., Poole, W.K., Passamani, E. N. Engl. J. Med. (1986) [Pubmed]
  6. Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications. Biggar, R.J. Clin. Cancer Res. (2012) [Pubmed]
  7. The serum digoxin test and digoxin toxicity: a Bayesian approach to decision making. Eraker, S.A., Sasse, L. Circulation (1981) [Pubmed]
  8. A V kappa-J kappa junctional change in an antidigoxin recombinant antibody destroys digoxin-binding activity. Hudson, N.W., Bruccoleri, R.E., Steinrauf, L.K., Hamilton, J.A., Mudgett-Hunter, M., Margolies, M.N. J. Immunol. (1990) [Pubmed]
  9. Effects of physical activity and immobilization on plasma digoxin concentration and renal digoxin clearance. Pedersen, K.E., Madsen, J., Kjaer, K., Klitgaard, N.A., Hvidt, S. Clin. Pharmacol. Ther. (1983) [Pubmed]
  10. Visual hallucinations as the earliest symptom of digoxin intoxication. Closson, R.G. Arch. Neurol. (1983) [Pubmed]
  11. Computer assisted prescribing of drugs. Mawer, G.E. Clinical pharmacokinetics. (1976) [Pubmed]
  12. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J., Wittes, J. N. Engl. J. Med. (1999) [Pubmed]
  13. Images in clinical medicine. Digoxin-induced bidirectional ventricular tachycardia. Valent, S., Kelly, P. N. Engl. J. Med. (1997) [Pubmed]
  14. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M., Shusterman, N.H. N. Engl. J. Med. (1996) [Pubmed]
  15. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. Scognamiglio, R., Rahimtoola, S.H., Fasoli, G., Nistri, S., Dalla Volta, S. N. Engl. J. Med. (1994) [Pubmed]
  16. Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle. Schenck-Gustafsson, K., Jogestrand, T., Nordlander, R., Dahlqvist, R. N. Engl. J. Med. (1981) [Pubmed]
  17. A comparison of digoxin and dobutamine in patients with acute infarction and cardiac failure. Goldstein, R.A., Passamani, E.R., Roberts, R. N. Engl. J. Med. (1980) [Pubmed]
  18. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. Cohn, J.N., Archibald, D.G., Ziesche, S., Franciosa, J.A., Harston, W.E., Tristani, F.E., Dunkman, W.B., Jacobs, W., Francis, G.S., Flohr, K.H. N. Engl. J. Med. (1986) [Pubmed]
  19. Sinus node dysfunction caused by methyldopa and digoxin. Davis, J.C., Reiffel, J.A., Bigger, J.T. JAMA (1981) [Pubmed]
  20. Effects of digoxin in infants with congested circulatory state due to a ventricular septal defect. Berman, W., Yabek, S.M., Dillon, T., Niland, C., Corlew, S., Christensen, D. N. Engl. J. Med. (1983) [Pubmed]
  21. Decreased bioavailability of digoxin due to antacids and kaolin-pectin. Brown, D.D., Juhl, R.P. N. Engl. J. Med. (1976) [Pubmed]
  22. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. Packer, M., Gheorghiade, M., Young, J.B., Costantini, P.J., Adams, K.F., Cody, R.J., Smith, L.K., Van Voorhees, L., Gourley, L.A., Jolly, M.K. N. Engl. J. Med. (1993) [Pubmed]
  23. A digoxin-antibiotic drug interaction. Doherty, J.E. N. Engl. J. Med. (1981) [Pubmed]
  24. Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. Doering, W. N. Engl. J. Med. (1979) [Pubmed]
  25. Fetal echocardiography for evaluation of in utero congestive heart failure. Kleinman, C.S., Donnerstein, R.L., DeVore, G.R., Jaffe, C.C., Lynch, D.C., Berkowitz, R.L., Talner, N.S., Hobbins, J.C. N. Engl. J. Med. (1982) [Pubmed]
  26. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Becker, M.L., Near, R., Mudgett-Hunter, M., Margolies, M.N., Kubo, R.T., Kaye, J., Hedrick, S.M. Cell (1989) [Pubmed]
  27. Predictors of postoperative myocardial ischemia in patients undergoing noncardiac surgery.The Study of Perioperative Ischemia Research Group. Hollenberg, M., Mangano, D.T., Browner, W.S., London, M.J., Tubau, J.F., Tateo, I.M. JAMA (1992) [Pubmed]
  28. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A., Borst, P. J. Clin. Invest. (1995) [Pubmed]
  29. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. DiBianco, R., Shabetai, R., Kostuk, W., Moran, J., Schlant, R.C., Wright, R. N. Engl. J. Med. (1989) [Pubmed]
  30. Alteration of digoxin pharmacokinetics by a single dose of quinidine. Chen, T.S., Friedman, H.S. JAMA (1980) [Pubmed]
  31. Inhibition of digoxin absorption by neomycin. Lindenbaum, J., Maulitz, R.M., Butler, V.P. Gastroenterology (1976) [Pubmed]
  32. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.P., Kirchgessner, T.G. J. Biol. Chem. (1999) [Pubmed]
  33. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. Lin, H., Juang, J.L., Wang, P.S. J. Biol. Chem. (2004) [Pubmed]
  34. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. Pavek, P., Merino, G., Wagenaar, E., Bolscher, E., Novotna, M., Jonker, J.W., Schinkel, A.H. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  35. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification. Chan, L.M., Cooper, A.E., Dudley, A.L., Ford, D., Hirst, B.H. Journal of drug targeting. (2004) [Pubmed]
  36. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Kim, R.B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M.F., Dempsey, P.J., Roden, M.M., Belas, F., Chaudhary, A.K., Roden, D.M., Wood, A.J., Wilkinson, G.R. Pharm. Res. (1999) [Pubmed]
  37. Spurious results of digoxin radioimmunoassay. Vinge, E., Nilsson, L.G., Molin, L., Ekman, R. N. Engl. J. Med. (1984) [Pubmed]
  38. Interaction between quinidine and digoxin. Leahey, E.B., Reiffel, J.A., Drusin, R.E., Heissenbuttel, R.H., Lovejoy, W.P., Bigger, J.T. JAMA (1978) [Pubmed]
WikiGenes - Universities